VNRX

VolitionRx Limited (VNRX) - 10-Q Summary for Period Ended June 30, 2025

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for VolitionRx Limited for the six-month period ended June 30, 2025. VolitionRx is a multi-national epigenetics company developing blood tests for early detection of cancer and sepsis using nucleosome biomarkers. The company is classified as a non-accelerated filer and a smaller reporting company. As of August 7, 2025, there were 107,595,421 shares of common stock outstanding.

Key Financial Metrics

Debt and Liquidity: The company holds significant long-term debt and convertible notes. As of June 30, 2025, total long-term debt (net of current portion) was $5,771,375, and convertible notes payable (net of current portion) were $2,920,242. Current liabilities ($9.24M) exceed current assets ($3.26M).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 15% year-over-year to $653,073, driven primarily by a 78% increase in service revenues ($277,254 vs. $155,866), while product revenues declined 9%.
• Expense Reduction: Total operating expenses decreased 22% to $12.47M. Research and Development (R&D) expenses dropped 36% to $5.33M due to reduced clinical trial activity and personnel costs. Sales and marketing expenses fell 36% to $1.96M.
• Net Loss Improvement: Net loss decreased 24% to $11.79M, attributed to lower operating expenses and a $418,681 gain on the change in fair value of a derivative liability.
• Financing Activity: The company raised significant capital in the period, including $5.8M net proceeds from a senior secured convertible note (Lind Offering) and $2.4M from a registered direct offering of common stock and warrants.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern beyond one year from the date of the report. The company has an accumulated deficit of $241.3M and relies on future financing, licensing, or grant funding to sustain operations.
• Unusual Items: The financial results include a non-cash gain of $418,681 related to the change in fair value of a derivative liability associated with the Lind convertible note. Additionally, $325,305 in amortization of debt discount was recorded as interest expense.
• Internal Controls: The company identified a material weakness in internal control over financial reporting, specifically regarding insufficient written documentation of policies and procedures for GAAP and SEC compliance. Remediation plans are ongoing.
• Outlook: The company plans to fund operations through further R&D, commercialization, and potential additional equity or debt financing. It aims to monetize intellectual property through licensing agreements.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.26M cash balance against the $10.6M operating cash burn rate for the six-month period.
• Debt Covenants: Review the terms of the $7.5M Lind convertible note, specifically the repayment schedule (monthly installments starting in November 2025) and conversion features that may lead to significant dilution.
• Going Concern Status: Assess the feasibility of management's plans to raise additional capital or secure licensing deals to mitigate the substantial doubt regarding the company's future.
• Revenue Sustainability: Evaluate the sustainability of the 78% growth in service revenues and the decline in product revenues.
• Internal Control Remediation: Monitor progress on remediation of the material weakness in internal controls to ensure future financial reporting reliability.